Skip Nav Destination
Drug Discovery
Emerging Drugs and Targets for Multiple Sclerosis
Edited by
Ana Martinez
Ana Martinez
Centro de Investigaciones Biologicas-CSIC, Spain
Search for other works by this author on:
Hardback ISBN:
978-1-78801-450-2
PDF ISBN:
978-1-78801-607-0
EPUB ISBN:
978-1-78801-806-7
Special Collection:
2019 ebook collection
Series:
Drug Discovery
No. of Pages:
333
Published online:
18 Jun 2019
Published in print:
28 Jun 2019
Book Chapter
CHAPTER 13: Non-coding RNA and Multiple Sclerosis: New Targets for Drug Discovery
By
David Otaegui
David Otaegui
Search for other works by this author on:
-
Published:18 Jun 2019
-
Special Collection: 2019 ebook collectionSeries: Drug Discovery
Page range:
285 - 301
Citation
I. Osorio-Querejeta, M. Muñoz-Culla, and D. Otaegui, in Emerging Drugs and Targets for Multiple Sclerosis, ed. A. Martinez, The Royal Society of Chemistry, 2019, pp. 285-301.
Download citation file:
Non-coding RNA (ncRNA) have been described to take part in several molecular pathways regulating cell functions. Hence, they have been postulated as possible therapeutic targets and mediators in several diseases. Regarding multiple sclerosis, they have been described to be involved in the regulation of the immune response and in remyelination. In this chapter, the role of ncRNA in inflammation and remyelination will be addressed, focusing on their therapeutic potential for multiple sclerosis.
You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Digital access
$64.60
